Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Beginning Cash Balance Beginning Cash Balance Capital Expenditures Capital Expenditures Cash from Discontinued Operations Cash from Discontinued Operations Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Dividends Paid - Common Dividends Paid - Common Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Other financing activities Other financing activities Preferred Shares Repurchased Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Cost of Revenue Gross Profit Leases Long-Term Debt Issuances Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Preferred Shares Repurchased Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Receivables - Other Shares Issued Shares Outstanding Shares Outstanding

Lisata Therapeutics (LSTA) Long-Term Debt Repayments (2016 - 2018)

Lisata Therapeutics filings provide 9 years of Long-Term Debt Repayments readings, the most recent being $23000.0 for Q3 2018.

For the quarter ending Q3 2018, Long-Term Debt Repayments rose 100.47% year-over-year to $23000.0, compared with a TTM value of $23000.0 through Jun 2019, down 83.04%, and an annual FY2018 reading of $159000.0, down 97.19% over the prior year.
Long-Term Debt Repayments hit $23000.0 in Q3 2018 for Lisata Therapeutics, down from $69000.0 in the prior quarter.
The five-year high for Long-Term Debt Repayments was $6.3 million in Q1 2016, with the low at -$5.9 million in Q2 2016.
Median Long-Term Debt Repayments over the past 5 years was $287070.5 (2014), compared with a mean of $555729.9.
The sharpest move saw Long-Term Debt Repayments skyrocketed 1696.53% in 2014, then plummeted 2265.39% in 2017.
Year by year, Long-Term Debt Repayments stood at $359668.0 in 2014, then surged by 165.34% to $954326.0 in 2015, then crashed by 67.02% to $314741.0 in 2016, then soared by 1452.58% to $4.9 million in 2017, then tumbled by 99.53% to $23000.0 in 2018.
According to Business Quant data, Long-Term Debt Repayments over the past three periods came in at $23000.0, $69000.0, and $67000.0 for Q3 2018, Q2 2018, and Q1 2018 respectively.